Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $6.7 million.

  • Abvc Biopharma's Total Liabilities rose 377.03% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 377.03%. This contributed to the annual value of $6.8 million for FY2024, which is 436.26% up from last year.
  • Abvc Biopharma's Total Liabilities amounted to $6.7 million in Q3 2025, which was up 377.03% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Total Liabilities registered a high of $9.7 million during Q2 2023, and its lowest value of $4.6 million during Q2 2022.
  • Moreover, its 5-year median value for Total Liabilities was $6.5 million (2023), whereas its average is $6.7 million.
  • Per our database at Business Quant, Abvc Biopharma's Total Liabilities crashed by 4651.44% in 2022 and then soared by 11049.95% in 2023.
  • Over the past 5 years, Abvc Biopharma's Total Liabilities (Quarter) stood at $4.8 million in 2021, then skyrocketed by 31.4% to $6.3 million in 2022, then grew by 2.96% to $6.5 million in 2023, then increased by 4.36% to $6.8 million in 2024, then fell by 1.94% to $6.7 million in 2025.
  • Its Total Liabilities was $6.7 million in Q3 2025, compared to $6.8 million in Q2 2025 and $6.9 million in Q1 2025.